Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceralasertib + carboplatin
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ceralasertib (AZD6738) is a potent and selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase, developed as an anticancer agent by AstraZeneca. By inhibiting ATR-mediated signaling, it disrupts DNA damage checkpoint activation and repair, leading to tumor cell apoptosis. Carboplatin is a cytotoxic platinum-based chemotherapy that acts primarily by alkylating DNA, causing cross-linking and preventing replication or transcription. The combination of ceralasertib with carboplatin aims to enhance antitumor activity by exploiting synthetic lethality in tumors with defective DNA repair mechanisms or high replication stress. This combination has been studied in phase I/II trials for advanced solid tumors including ovarian, lung, gastric, breast cancers, and others[1][2][5][7].
- Other names
- ceralasertib + carboplatin
02
Targets
DNAATR (ATR serine/threonine kinase)
Beyond the preview
Go deeper on Ceralasertib + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ceralasertib + carboplatin.